Sign up to save your podcasts
Or
Share Treatment Options for HER2 Positive Biliary Tract Cancers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treatment Options for HER2 Positive Biliary Tract Cancers
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.
In this episode, we cover:
• The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers.
• Who should be tested for HER2 positivity and how to classify HER2-positive disease.
• The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status.
• Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab.
• The significance of patient-centered decision-making and managing side effects associated with these treatments.
• Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance.
Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.
In this episode, we cover:
• The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers.
• Who should be tested for HER2 positivity and how to classify HER2-positive disease.
• The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status.
• Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab.
• The significance of patient-centered decision-making and managing side effects associated with these treatments.
• Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance.
Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
502 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners